Bayer runs into another German roadblock in marketing vision drug Eylea

The high-flying eye drug Eylea has hit some more turbulence in Germany. The country's cost-effectiveness watchdog said the Bayer drug doesn't perform any better than its Novartis ($NVS) rival, Lucentis, as a treatment for diabetic macular edema. The same group, the German Institute for Quality and Efficiency in Health Care (IQWiG), has said it was unable to assess the drug as a treatment for age-related macular degeneration because Bayer didn't provide enough relevant data. IQWiG's assessments are used by public insurers to determine how much to pay for drugs. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.